dragon14 said:
I am looking for some input on a good cycle for an athlete. No drug testing worries.
Strength much more important than size.
Something good for tendons and ligaments a plus.
Weight: 215
Need to keep weight about the same (or less). Can't get any heavier due to weight class restrictions.
Think boxer or kickboxer.
Thanks bros.
BTW: last cycle sus 250 only for 8 weeks - gained about 20 pounds - bad acne
A combination of Oxandrolone and HGH.
These substances are only an aid to obtaining your goals. You can expect an increase in strength, decrease in body fat, enhanced revcovery ability and strengthening of your connective tissues with these two drugs factored in to your overall program. Also, drug testing, if and when necessary, is easily delt with on these two substances. Your specific Anaerobic/Aerobic training and conditiong combined with nutrition and rest will be the ultimate determining factor in stimulating your body and providing it with the necessary nutrition and recovery time to obtain your results.
Here are a few studies on Oxandrolone and HGH to get you started:
Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults1
Linda J. Woodhouse, Sylvia L. Asa, Scott G. Thomas and Shereen Ezzat
Departments of Physical Therapy, Laboratory Medicine and Pathobiology, and Medicine, The University of Toronto, Toronto, Ontario M5G 1X5, Canada
The impact of GH on functional performance in GH-deficient adults is not well understood. To investigate the effects of GH on skeletal muscle, physical, and functional capacity, we randomized 28 GH-deficient adults to receive 3 months of recombinant human GH [rhGH: somatotropin, 6.25 µg/kg lean body mass (LBM) for 1 month, 12.5 µg/kg LBM thereafter] in a double-blind placebo-controlled cross-over trial. We measured muscle fiber type, size, and insulin-like growth factor I messenger RNA, aerobic capacity [maximal oxygen uptake (VO2max), ventilation threshold (VeT)], isokinetic strength, oxygen-cost-of-walking at normal and fast speeds, and fatigue determined by the profile of mood states questionnaire. As expected, GH treatment decreased body fat, increased LBM, increased muscle fiber size, and increased muscle insulin-like growth factor-I messenger RNA 5-fold; however, muscle strength remained unchanged. At baseline, VeT occurred at a high percentage of maximal VO2max (73.3% ± 2.6) because of low VO2max (1.74 ± 0.1 L/min or 20.7 ± 1.3 mL/kg·min). Walking required high oxygen consumptions representing from 83 ± 4% of VeT at normal speeds to 120 ± 5% of VeT at fast speeds. After rhGH, there was a significant (P = 0.03) increase in VeT (18%), compared with placebo. This was paralleled by a nonsignificant rise in VO2max. Functionally, rhGH treatment decreased the oxygen cost of walking, relative to VeT, at normal (14% decrease, P = 0.019) and fast (21% decrease, P = 0.004) SPW speeds. A 3-variable model (baseline fast SPW speed, VeT/VO2max, and VeT) accounted for 39% of the variance of change in self-reported fatigue. These data indicate that GH-deficient adults require a high fraction of VeT for daily activities, explaining the perception of increased fatigue and impaired physical performance. The actions of rhGH on muscle fiber size translate into physiological improvement in submaximal aerobic capacity and result in functional improvement in walking ability but do not necessarily alter strength. Thus, measures of effort-independent submaximal aerobic performance provide novel objective determinants of functional impairment and fatigue and can be used to evaluate and predict response to GH treatment.
Short-Term Oxandrolone Administration Stimulates Net Muscle Protein Synthesis in Young Men1
Melinda Sheffield-Moore, Randall J. Urban, Steven E. Wolf, J. Jiang, Don H. Catlin, David N. Herndon, Robert R. Wolfe and Arny A. Ferrando
Short term administration of testosterone stimulates net protein synthesis in healthy men. We investigated whether oxandrolone [Oxandrin (OX)], a synthetic analog of testosterone, would improve net muscle protein synthesis and transport of amino acids across the leg. Six healthy men [22 ± 1 (±SE) yr] were studied in the postabsorptive state before and after 5 days of oral OX (15 mg/day). Muscle protein synthesis and breakdown were determined by a three-compartment model using stable isotopic data obtained from femoral arterio-venous sampling and muscle biopsy. The precursor-product method was used to determine muscle protein fractional synthetic rates. Fractional breakdown rates were also directly calculated. Total messenger ribonucleic acid (mRNA) concentrations of skeletal muscle insulin-like growth factor I and androgen receptor (AR) were determined using RT-PCR. Model-derived muscle protein synthesis increased from 53.5 ± 3 to 68.3 ± 5 (mean ± SE) nmol/min·100 mL/leg (P < 0.05), whereas protein breakdown was unchanged. Inward transport of amino acids remained unchanged with OX, whereas outward transport decreased (P < 0.05). The fractional synthetic rate increased 44% (P < 0.05) after OX administration, with no change in fractional breakdown rate. Therefore, the net balance between synthesis and breakdown became more positive with both methodologies (P < 0.05) and was not different from zero. Further, RT-PCR showed that OX administration significantly increased mRNA concentrations of skeletal muscle AR without changing insulin-like growth factor I mRNA concentrations. We conclude that short term OX administration stimulated an increase in skeletal muscle protein synthesis and improved intracellular reutilization of amino acids. The mechanism for this stimulation may be related to an OX-induced increase in AR expression in skeletal muscle.